The present invention discloses either or both in situ and a priori generated hydrogel wound dressings comprise one or more RTR components in low viscosity aqueous solution and one or more non-RTR components. A dressing, comprising at least one first RTR and an active component (AC) integrated within the RTR is also disclosed. The invention further discloses a method of treating a medical or cosmetic indication by a wound dressing, comprising either or both in situ and a priori generating hydrogel wound dressings by providing one or more RTR components in low viscosity aqueous solution and one or more non-RTR components. it and methods for treating a medical or cosmetic indication by providing a dressing with at least one first RTR and with at least one active component (AC) integrated within the RTR are also disclosed.

The present invention discloses either or both in situ and a priori generated hydrogel wound dressings comprise one or more RTR components in low viscosity aqueous solution and one or more non-RTR components. A dressing, comprising at least one first RTR and an active component (AC) integrated within the RTR is also disclosed. The invention further discloses a method of treating a medical or cosmetic indication by a wound dressing, comprising either or both in situ and a priori generating hydrogel wound dressings by providing one or more RTR components in low viscosity aqueous solution and one or more non-RTR components. it and methods for treating a medical or cosmetic indication by providing a dressing with at least one first RTR and with at least one active component (AC) integrated within the RTR are also disclosed.

The present invention provides a medical dressing article and a method of manufacturing the same, which comprises: (a) a first layer comprised of polycaprocaptone fibers having a PCL fiber diameter of 0.5 μm and 2.9 μm; (b) a second layer, deposited directly on the first layer, including a mixture of polycaprolactone and poloxamer fibers (PCL and POX fibers) wherein a PCL and POX fiber diameter is between 0.1 μm and 4 μm; and (c) a third layer, deposited directly on the second layer, further comprising a mixture of gelatin and silver nitrate (AgNO.sub.3).

The present invention provides novel compositions comprising multipotent cells or microvascular tissue, wherein the cells or tissue has been sterilized and/or treated to inactivated viruses, and related methods of using these compositions to treat or prevent tissue injury or disease in an allogeneic subject.

Disclosed embodiments relate to a wound dressing which can generate nitric oxide. The wound dressing may include a cover layer, an activator layer such as an acid providing layer and nitric oxide source layer, such as a nitrite providing layer. The activator layer may include acidic groups and may be hydrogel, xerogel, or other suitable material. The nitric oxide source layer may include a nitrite salt. Nitrite ions of the nitric oxide source layer may react with the acidic groups of the activating layer to generate nitric oxide. The activating layer may include a window at the center, and a central absorbent material may be positioned at the window. Various separating layers may also be incorporated into the dressing to control the interaction between activating layer and nitric oxide source layer.

A microporous gel system for certain applications, including biomedical applications, includes an aqueous solution containing plurality of microgel particles including a biodegradable crosslinker. In some aspects, the microgel particles act as gel building blocks that anneal to one another to form a covalently-stabilized scaffold of microgel particles having interstitial spaces therein. In certain aspects, annealing of the microgel particles occurs after exposure to an annealing agent that is endogenously present or exogenously added. In some embodiments, annealing of the microgel particles requires the presence of an initiator such as exposure to light. In particular embodiments, the chemical and physical properties of the gel building blocks can be controlled to allow downstream control of the resulting assembled scaffold. In one or more embodiments, cells are able to quickly infiltrate the interstitial spaces of the assembled scaffold.

The present invention provides a liquid bandage containing peptide anti-inflammatory active ingredient and a preparation method thereof, which relates to the technical field of medical materials. The liquid bandage comprises film-forming agents; one or more plasticizers, comprising glycerin; one or more anti-inflammatory substances, comprising oligopeptide with an amino acid sequence of Leu-Leu-Phe-Thr-Thr-Gln; and solvent, comprising deionized water. The liquid bandage can promote the expression of interleukin 10 (IL-10) and inhibit the expressions of interleukin 6 (IL-6) and tumor necrosis factor (TNF-α). Peptide anti-inflammatory active ingredient can produce good anti-inflammatory activity. Further, the liquid bandage can enhance the close contact between gel and the injured skin surface, increase the cleanliness of the wound surface, and can increase a clearance rate of inflammatory cells.

The present invention provides radical crosslinked zwitterionic gels, methods of preparing the radical crosslinked zwitterionic gels, and methods of using the radical crosslinked zwitterionic gels for treating a wound.

The present invention relates to a wound dressing composition that is capable of gelling upon contact with a fluid derived from a human or animal body, and which is able to maintain the integrity of the gel for a period of time that is longer than about 24 hours.

Methods for intravesical administration of a therapeutic agent including application of a photoactive nanogel to the mucosal surfaces of the bladder and/or intravesical application of cell-penetrating peptides. Photoactive nanogels may be aggregated by exposure to ultraviolet light, either in vitro or in vivo, to provide controlled or extended release of a therapeutic agent, such as an antibiotic.